Gartner, Inc. (IT) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 2.31%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 2.31% | Share-based compensation / revenue. Period ending 2026-06-30. $149.54M ÷ $6.46B × 100 ≈ 2.31% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 6.46B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 149.54M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 1.12B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $6.46B | $149.54M | $1.12B | (m) | (m) | 2.31% | (m) | (m) |
| 2026-03-31 | (m) | $6.47B | $151.58M | $1.06B | (m) | (m) | 2.34% | (m) | (m) |
| 2025-12-31 | (m) | $6.50B | $155.88M | $1.03B | (m) | (m) | 2.40% | (m) | (m) |
| 2025-09-30 | (m) | $6.46B | $153.91M | $1.01B | (m) | (m) | 2.38% | (m) | (m) |
| 2025-06-30 | (m) | $6.42B | $157.73M | $1.17B | (m) | (m) | 2.46% | (m) | (m) |
| 2025-03-31 | (m) | $6.33B | $154.45M | $1.16B | (m) | (m) | 2.44% | (m) | (m) |
| 2024-12-31 | (m) | $6.27B | $154.78M | $1.16B | (m) | (m) | 2.47% | (m) | (m) |
| 2024-09-30 | (m) | $6.14B | $150.11M | $1.14B | (m) | (m) | 2.45% | (m) | (m) |
| 2024-06-30 | (m) | $6.06B | $142.81M | $1.14B | (m) | (m) | 2.36% | (m) | (m) |
| 2024-03-31 | (m) | $5.97B | $135.29M | $1.10B | $124.60M | (m) | 2.27% | 8.85× | Reported |
| 2023-12-31 | (m) | $5.91B | $129.84M | $1.24B | $132.77M | (m) | 2.20% | 9.32× | Reported |
| 2023-09-30 | (m) | $5.83B | $117.35M | $1.27B | $108.57M | (m) | 2.01% | 11.68× | Reported |
| 2023-06-30 | (m) | $5.75B | $111.27M | $1.28B | $117.04M | (m) | 1.94% | 10.91× | Reported |
| 2023-03-31 | (m) | $5.62B | $103.49M | $1.29B | $122.20M | (m) | 1.84% | 10.56× | Reported |
| 2022-12-31 | (m) | $5.48B | $90.57M | $1.10B | $126.20M | (m) | 1.65% | 8.72× | Reported |
| 2022-09-30 | (m) | $5.28B | $94.41M | $953.19M | $124.77M | (m) | 1.79% | 7.64× | Reported |
| 2022-06-30 | (m) | $5.10B | $92.87M | $929.99M | $126.09M | (m) | 1.82% | 7.38× | Reported |
| 2022-03-31 | (m) | $4.89B | $94.61M | $907.59M | $123.76M | (m) | 1.93% | 7.33× | Reported |
| 2021-12-31 | (m) | $4.73B | $98.57M | $915.75M | $118.51M | (m) | 2.08% | 7.73× | Reported |
| 2021-09-30 | (m) | $4.54B | $87.93M | $908.48M | $113.59M | (m) | 1.94% | 8.00× | Reported |
| 2021-06-30 | (m) | $4.38B | $84.01M | $765.91M | $112.53M | (m) | 1.92% | 6.81× | Reported |
| 2021-03-31 | (m) | $4.18B | $73.50M | $590.84M | $115.44M | (m) | 1.76% | 5.12× | Reported |
| 2020-12-31 | (m) | $4.10B | $62.54M | $490.15M | $115.64M | (m) | 1.53% | 4.24× | Reported |
| 2020-09-30 | (m) | $4.19B | $67.42M | $448.16M | $116.34M | (m) | 1.61% | 3.85× | Reported |
| 2020-06-30 | (m) | $4.20B | $64.88M | $429.66M | $109.88M | (m) | 1.55% | 3.91× | Reported |
| 2020-03-31 | (m) | $4.29B | $62.32M | $446.01M | $104.33M | (m) | 1.45% | 4.27× | Reported |
| 2019-12-31 | (m) | $4.25B | $69.01M | $370.09M | $102.83M | (m) | 1.63% | 3.60× | Reported |
| 2019-09-30 | (m) | $4.13B | $68.05M | $363.55M | $100.80M | (m) | 1.65% | 3.61× | Reported |
| 2019-06-30 | (m) | $4.05B | $65.81M | $347.13M | $103.71M | (m) | 1.62% | 3.35× | Reported |
| 2019-03-31 | (m) | $3.98B | $67.03M | $317.23M | $116.56M | (m) | 1.68% | 2.72× | Reported |
| 2018-12-31 | (m) | $3.98B | $66.17M | $259.71M | $126.77M | (m) | 1.66% | 2.05× | Reported |
| 2018-09-30 | (m) | $3.90B | $67.03M | $193.00M | $138.97M | (m) | 1.72% | 1.39× | Reported |
| 2018-06-30 | (m) | $3.81B | $70.67M | $115.93M | $150.75M | (m) | 1.86% | 0.77× | Reported |
| 2018-03-31 | (m) | $3.65B | $87.33M | $-68.55M | $157.10M | (m) | 2.39% | -0.44× | Reported |
| 2017-12-31 | (m) | $3.31B | $78.94M | $-6.33M | $127.95M | (m) | 2.38% | -0.05× | Reported |
| 2017-09-30 | (m) | $3.00B | $78.46M | $39.46M | $96.89M | (m) | 2.62% | 0.41× | Reported |
| 2017-06-30 | (m) | $2.75B | $73.63M | $112.54M | $64.06M | (m) | 2.68% | 1.76× | Reported |
| 2017-03-31 | (m) | $2.51B | $53.74M | $294.23M | $27.46M | (m) | 2.14% | 10.71× | Reported |
| 2016-12-31 | (m) | $2.44B | $46.66M | $305.14M | $27.57M | (m) | 1.91% | 11.07× | Reported |
| 2016-09-30 | (m) | $2.39B | $45.30M | $298.07M | $27.07M | (m) | 1.90% | 11.01× | Reported |
| 2016-06-30 | (m) | $2.31B | $45.36M | $301.82M | $27.19M | (m) | 1.96% | 11.10× | Reported |
| 2016-03-31 | (m) | $2.25B | $44.91M | $303.74M | $25.07M | (m) | 2.00% | 12.11× | Reported |
| 2015-12-31 | (m) | $2.16B | $46.15M | $288.00M | $22.55M | (m) | 2.13% | 12.77× | Reported |
| 2015-09-30 | (m) | $2.10B | $46.40M | $282.22M | $19.48M | (m) | 2.21% | 14.49× | Reported |
| 2015-06-30 | (m) | $2.07B | $45.62M | $279.13M | $16.09M | (m) | 2.20% | 17.35× | Reported |
| 2015-03-31 | (m) | $2.05B | $41.82M | $275.67M | $13.53M | (m) | 2.04% | 20.38× | Reported |
| 2014-12-31 | (m) | $2.02B | $38.84M | $286.16M | $12.30M | (m) | 1.92% | 23.27× | Reported |
| 2014-09-30 | (m) | $1.96B | $37.11M | $279.08M | $11.27M | (m) | 1.90% | 24.76× | Reported |
| 2014-06-30 | (m) | $1.90B | $35.78M | $288.43M | $10.74M | (m) | 1.89% | 26.86× | Reported |
| 2014-03-31 | (m) | $1.82B | $36.15M | $280.66M | $10.20M | (m) | 1.98% | 27.51× | Reported |
| 2013-12-31 | (m) | $1.78B | $34.73M | $275.49M | $10.39M | (m) | 1.95% | 26.52× | Reported |
| 2013-09-30 | (m) | $1.74B | $35.41M | $266.40M | $-9.76M | (m) | 2.04% | (m) | Reported |
| 2013-06-30 | (m) | $1.70B | $37.15M | $257.42M | $-9.67M | (m) | 2.18% | (m) | Reported |
| 2013-03-31 | (m) | $1.65B | $37.78M | $246.16M | $-10.15M | (m) | 2.29% | (m) | Reported |
| 2012-12-31 | (m) | $1.62B | $36.38M | $245.71M | $-9.90M | (m) | 2.25% | (m) | Reported |
| 2012-09-30 | (m) | $1.57B | $36.14M | $235.51M | $12.52M | (m) | 2.30% | 18.81× | Reported |
| 2012-06-30 | (m) | $1.54B | $34.67M | $232.99M | $9.98M | (m) | 2.25% | 23.34× | Reported |
| 2012-03-31 | (m) | $1.51B | $34.64M | $221.84M | $10.63M | (m) | 2.30% | 20.87× | Reported |
| 2011-12-31 | (m) | $1.47B | $32.87M | $214.06M | $11.22M | (m) | 2.24% | 19.09× | Reported |
| 2011-09-30 | (m) | $1.42B | $34.09M | $197.67M | $15.07M | (m) | 2.40% | 13.12× | Reported |
| 2011-06-30 | (m) | $1.37B | $33.59M | $183.19M | $15.79M | (m) | 2.45% | 11.60× | Reported |
| 2011-03-31 | (m) | $1.32B | $32.64M | $165.85M | $16.17M | (m) | 2.47% | 10.26× | Reported |
| 2010-12-31 | (m) | $1.29B | $32.63M | $149.26M | $16.77M | (m) | 2.53% | 8.90× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $1.14B | $26.07M | $134.48M | $16.86M | (m) | 2.29% | 7.98× | Reported |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $1.28B | $20.70M | $164.37M | $22.39M | (m) | 1.62% | 7.34× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evolent Health, Inc. (EVH) | United States | $0.397B | -1.21 |
| FRANKLIN COVEY CO (FC) | United States | $0.195B | 123.76 |